Subscribe to our free newsletter today to keep up to date with the latest manufacturing news.

CSL Behring plans to invest $1.5 billion to expand its manufacturing operations in Illinois, a move that will establish end to end plasma processing capacity in the United States and strengthen production of therapies used to treat rare diseases.

The Australian biotechnology company announced a major expansion of its facility in Kankakee County, Illinois, where the investment will support new manufacturing infrastructure, increase production capacity and create hundreds of skilled jobs.

The project is expected to add around 300 permanent positions to the facility’s existing workforce of roughly 1,200 employees. Construction of the expanded manufacturing site is also expected to support around 800 additional jobs during the development phase.

CSL Behring, the company’s biopharmaceutical division, produces plasma derived therapies used to treat patients with immune disorders, bleeding conditions and other rare diseases.

The planned investment will bring the full plasma processing chain into the United States, allowing the company to collect, process and manufacture plasma based therapies within a more integrated domestic production network.

Plasma therapies are derived from proteins found in blood plasma and are used to treat a wide range of medical conditions. These treatments are particularly important for patients with immune deficiencies who rely on antibody therapies to help their bodies fight infection.

Unlike many pharmaceutical products, plasma cannot be synthetically manufactured. Instead, it must be collected from human donors and then undergo a highly controlled process of testing, purification and protein extraction before it can be used in medical treatments.

Producing plasma derived therapies is therefore both resource intensive and heavily regulated. Treating a single patient for a year may require plasma collected from hundreds or even thousands of individual donations.

The expansion in Illinois is designed to strengthen supply chains for these treatments at a time when global demand for plasma therapies continues to rise.

Industry analysts say investments in domestic plasma processing capacity are increasingly important for improving supply stability and reducing dependence on complex international supply networks.

State officials say the project will also deliver a significant economic boost for the Kankakee region.

The expansion is supported in part by Illinois’ Economic Development for a Growing Economy tax credit program, commonly known as EDGE. The program offers tax incentives to companies that create jobs and invest in long term economic development projects within the state.

EDGE incentives can include tax credits tied to new hiring, job retention and employee training programs. The program has been used to attract major manufacturing and technology investments to Illinois since its introduction in 1999.

Local infrastructure planning has also played a role in preparing for the project. State and regional authorities have coordinated improvements to transportation and energy infrastructure to support the facility’s expansion.

Those efforts include transportation options to connect workers with the site as well as upgrades to local roads, traffic systems and energy supply needed to support a larger manufacturing operation.

Officials say these improvements are expected to benefit the wider community by supporting additional economic activity and long term regional development.

The investment reflects the growing importance of plasma derived therapies within the global healthcare system.

Treatments based on plasma proteins are widely used to manage conditions such as immune deficiencies, neurological disorders and bleeding diseases. For many patients these therapies are not only essential for long term health but also life saving.

Patient advocacy groups say maintaining a stable supply of plasma therapies is critical because shortages can have serious consequences for those who depend on regular treatment.

As demand continues to grow, biotechnology companies are investing heavily in collection networks, processing facilities and manufacturing capacity to expand production.

CSL has already invested billions of dollars in its US operations, including a network of hundreds of plasma collection centres across the country. The Illinois expansion represents another step in strengthening the company’s manufacturing capabilities within the United States.

For the biotechnology sector, projects like the Kankakee expansion highlight the increasing importance of advanced manufacturing and domestic supply chains in supporting the development and distribution of complex medical therapies.

Sources

Eye Witness News